Head and Neck Cancer · Chemo-radiotherapy · Second malignancies · Late effects Summary Background: Chemo-radiotherapy is superior to radiotherapy alone in the treatment of advanced, inoperable head and neck cancer. The long-term treatment results, the induction of second malignant tumors, and other long-term toxicities are not well defined. Patients and Methods: 100 consecutive patients with advanced head and neck cancer who were treated at our center were studied. Treatment results, survival, the occurrence of late complications, and second malignant tumors (SMT) were investigated. 78 patients were treated with a protocol combining cisplatinum, 5-fluorouracil, folinic acid and hyperfractionated irradiation. 22 patients were treated with other chemo-radiotherapy protocols. The relative risk of developing an SMT was compared with that within the normal population. Results: The cumulative total probability of survival was 51.1% at 2 years and 38.7% at 4 years. The probability of relapse-free survival was 39.9% at 2 years and 36.7% at 4 years. A total of 7 patients developed SMT (4 cases of lung cancer, 2 colon cancers, 1 skin cancer). After 6 years, a cumulative risk of SMT of 8.7% was observed. The relative risk of developing an SMT was significantly increased (4.45-fold in males) compared with a normal population. 13 of 38 evaluable patients (34.2%) had severe late complications like fibrosis of soft tissues, nerve lesions, or were dependent on tracheal cannulas.
Summary
Background: Chemo-radiotherapy is superior to radiotherapy alone in the treatment of advanced, inoperable head and neck cancer. The long-term treatment results, the induction of second malignant tumors, and other long-term toxicities are not well defined. Patients and Methods: 100 consecutive patients with advanced head and neck cancer who were treated at our center were studied. Treatment results, survival, the occurrence of late complications, and second malignant tumors (SMT) were investigated. 78 patients were treated with a protocol combining cisplatinum, 5-fluorouracil, folinic acid and hyperfractionated irradiation. 22 patients were treated with other chemo-radiotherapy protocols. The relative risk of developing an SMT was compared with that within the normal population. Results: The cumulative total probability of survival was 51.1% at 2 years and 38.7% at 4 years. The probability of relapse-free survival was 39.9% at 2 years and 36.7% at 4 years. A total of 7 patients developed SMT (4 cases of lung cancer, 2 colon cancers, 1 skin cancer). After 6 years, a cumulative risk of SMT of 8.7% was observed. The relative risk of developing an SMT was significantly increased (4.45-fold in males) compared with a normal population. 13 of 38 evaluable patients (34.2%) had severe late complications like fibrosis of soft tissues, nerve lesions, or were dependent on tracheal cannulas.
Conclusions:
The treatment results and long-term prognoses in our population of unselected high-risk patients are unsatisfactory, but comparable to those from multicenter studies. About 35% of patients become long-term (> 4 years) survivors. SMT generally occur early, have a poor prognosis and, most likely, are not treatment-related. Approximately 30% of long-term survivors have severe, often incapacitating late effects. The treatment and -if possible -prevention of these late effects is important for the quality of life of patients who survived advanced head and neck cancer.
Advanced Head and Neck Cancer: Long-Term Results of Chemo-Radiotherapy, Complications and Induction of Second Malignancies Introduction
In the 1980s, patients with locoregionally advanced head and neck cancer had a poor prognosis. Conventional therapy, surgery and radiation, led to long-term survival or even cure in fewer than 20% of patients. The introduction of platinumbased chemo-radiotherapy has improved the response and possibly the cure rate of patients with advanced head and neck cancer and can now be considered as the standard of care [1] [2] [3] . The rationale of chemo-radiotherapy with hyperfractionated irradiation is that tumor cells are sensitized to radiation and thereby the resistance of tumor cells is overcome. A meta-analysis of 63 trials concluded that chemotherapy added to locoregional treatment provided a benefit in survival rate of 4% at 2 and at 5 years [4] . It is known that modern chemo-radiotherapy entails a considerable acute toxicity (e.g. mucositis) and some long-term complications like radiation fibrosis and xerostomia. In addition, the treatment of patients with head and neck cancer is complicated by comorbidity. If all types of cancer are considered, the induction of second malignant tumors (SMT) is a serious problem [5] . For example, the long-term treatment results of patients with Hodgkin's disease and testicular cancer are negatively influenced by the occurrence of SMT. Patients with head and neck cancer are predisposed to second tumors by the field cancerization due to tobacco and other carcinogens. Additional factors may be genetic influences, age, and treatment-related factors. Previous studies reported a widely different incidence of second cancer after the diagnosis of head and neck cancer [6, 7] . Recently, Merlano et al. [8] reported that patients with head and neck cancer treated with chemo-radiotherapy developed more second cancers than patients treated only with radiation. However, in that study , the total survival was still superior in the group of patients treated with chemo-radiotherapy compared to the radiation group. In the present study we investigated the patients treated at our center with combined chemo-radiotherapy for the long-term treatment results, late complications and for the occurrence of SMT.
Patients and Methods
All patients treated at our center between January 1988 and June 2000 (10 years and 6 months) with combined chemo-radiotherapy were included in the present study. 4 patients were excluded because the records were insufficient, and 3 patients were excluded because of a preexisting malignant tumor. Clinical characteristics of the patients are shown in table 1. 78 patients were treated with an intensive protocol combining cisplatinum, 5-fluorouracil, folinic acid and hyperfractionated irradiation [1, 2] . The remaining 22 patients were treated with less intensive chemo-radiotherapy, mainly because of age and reduced performance status. In these 22 patients, combinations of 5-fluorouracil and mitomycin-C were used as chemotherapy. Before beginning the treatment, 24 patients underwent a surgical tumor reduction (13 patients had radical neck dissection, 2 patients had radical neck dissection and radical tumor surgery, 5 patients had a palliative Munker/Purmale/Aydemir/Reitmeier/ Pohlmann/Schorer/Hartenstein tumor reduction, and 4 patients had a palliative tumor reduction and a selective neck dissection). In 3 patients, a tracheostomy was necessary before beginning the treatment. Fractionated radiotherapy was performed with a cobalt-60 source (Siemens Gammatron-1; patients treated until 9/97) and a linear accelerator (Siemens Linac MD-2; patients treated after 9/97). Treatment planning was individualized by computed tomography. Amifostine was not routinely administered during radiotherapy. Follow-up was obtained from outpatient records, and by contacting the patient or his physician by telephone. Follow-up was complete in 96 cases (information about clinical status within 12 months of last attempted contact). A complete clinical response was defined as no evidence of disease 3 months after combined treatment. If radiological abnormalities persisted, the patient was evaluated at the next follow-up visit, and was termed complete response if no progression had developed. Late effects were evaluated if the patient had survived at least 1 year after diagnosis, did not have an SMT, and was available for an interview or if adequate records were present. The diagnosis of SMT was made if a tumor showed a histology different from that of the initial tumor and/or a clinical presentation of a second unrelated tumor.
Statistical Methods
Survival, relapse-/progression-free survival and the occurrence of SMT were estimated by Kaplan-Meier analysis. SPSS, version 10, was used for data analysis and statistical calculations. Patients who developed SMT were censored for relapse-/progression-free survival. 38 patients were evaluable for treatment-related late effects (median follow-up 46 months after diagnosis). Dryness of mouth of any degree, hypothyroidism, altered taste, hoarseness were considered as minor complications. Bone necrosis, chronic ulcers, fistulas, nerve lesions, laryngeal or esophageal stenoses were considered as major complications. Advanced Head and Neck Cancer 555
As a reference data base for the tumor incidence in the general population, the Saarland cancer registry was used (reference year 1996). For the calculation of relative risk of SMT, the categories 141, 143-149, 161 (ICD 9) were excluded. Age-and gender-specific incidence rates from the normal population were multiplied by the corresponding person-years of observation to obtain the expected number of tumors. The estimation of relative risk (ratio of observed to expected number of cases) was based on the assumption that the observed number of SMT followed a Poisson distribution. Confidence intervals for relative risks were calculated using exact Poisson limits. The estimation of relative risk is statistically significant if the confidence intervals do not overlap the unity.
Results

Survival and Relapse-Free Survival
The total survival rates are shown in figure 1a . At 24 months, the total cumulative survival probability was 51.1%, at 48 months it was 38.7%. If only patients are considered who had an intensive cisplatinum-containing chemotherapy, the total cumulative survival rate was 56.6% at 2 years and 44.3% at 4 years. The Kaplan-Meier analysis for these patients in comparison with other chemo-radiotherapy regimens is shown in figure 1b . If patients are considered who are aged 54 or younger and compared with older patients, the younger patients survived slightly longer than older patients (mean survival time 51 versus 46 months). However, the Kaplan-Meier analysis showed no significant difference between younger (<55 years) and older patients ( fig. 1c) . No significant difference could also be found for sex, extent of disease (stage III versus stage IV), and location (oropharynx and oral cavity versus larynx and hypopharynx, data not shown). The analysis of relapse-or progression-free survival time is shown in figure  2 . The cumulative survival probability at 24 months for relapse-or progression-free patients was 39.9%, at 48 months it was 36.7%. A total of 20 patients survived 4 or more years without evidence of relapse. A complete clinical response was found in 43/76 evaluable patients (56.6%).
Second Malignant Tumors
A total of 7 patients developed SMT (4 lung cancers, 2 colon cancers and one basal cell skin cancer; table 2). The cumulative incidence of SMT is shown in figure 3 . After 6 years, a cu- 
Late Complications
All patients had some degree of functional impairment following chemo-radiotherapy. In 13/38 patients (34.2%) major late complications were observed (table 4) . If only patients in complete remission and with more than 4 years of follow-up were considered, major complications were seen in 9/19 evaluable patients (47.4%).
Discussion
Our treatment results of chemo-radiotherapy in patients with advanced head and neck cancer are comparable to those from large multicenter and single-center studies [1, 2, 8, [10] [11] [12] . Approximately 50% of patients survived for 2 years, and approximately 35% survived free from relapse or progression for 4 years. These results were reached despite a majority of stage IV patients and a median age of 54 years. The treatment results published here appear similar to those of a phase II study published a decade earlier [13] ; however, in the earlier study only selected patients with a mean age of 47 years were treated. The present results actually show an improvement in the standard of care, most likely due to advances in supportive care. Of all patients who fail treatment, most die from tumor progression, some die from treatment complications or SMT. The development of second, histogenetically unrelated neoplasms is a problem recognized in patients with Hodgkin's disease [5, 10] and other good-prognosis tumors like testicular cancer [14] , but may also be observed in other tumors. It was mulative risk of 8.7%, after 8 years a cumulative risk of 16.3% was observed. All patients with SMT were male. The interval between the diagnosis of head and neck cancer and SMT varied between 0 months and 8 years (median time to diagnosis of SMT: 13 months). In 5 patients the primary head and neck tumor was in remission, in 2 patients active tumor was present. The prognosis of patients with SMT was generally poor: the 4 patients with lung cancer survived 1, 2+, 4+ and 13 months after the diagnosis of SMT, both patients with colon cancer survived only 3 months after the diagnosis of SMT. The relative risk of developing an SMT was significantly increased (4.45-fold in males, 4.09-fold if both sexes are considered) compared with a normal population ( shown earlier that some SMT are related to the treatment administered. In patients with head and neck cancer, the continued influence of carcinogens like tobacco and alcohol may lead to second cancer. Previous studies indicate that 10-30% of patients develop SMT [6, 7, [15] [16] [17] [18] . However, these studies include patients treated in the 1980s, in different stages and with different treatment modalities. Few studies examine patients treated with combined chemotherapy and radiation for their risk of SMT. A list of studies involving chemo-radiotherapy is given in [27] . However, the longer survival and possible cure of a fraction of patients treated with chemo-radiotherapy will favor the appearance of SMT. At present, the major problem in advanced head and neck cancer is local relapse and refractory disease, not death from SMT. A prospective comparison with patients who were treated with unique radiation may determine to what extent SMT are influenced by chemotherapy. Laser surgery should also be integrated in the concept of multimodal treatment and may lead to a further improvement in the long-term prognosis [28] . Quality of life issues are increasingly important for patients with head and neck cancer [29, 30] . Most studies focus on acute toxicities, swallowing disabilities, dry mouth, hoarseness, and mouth pain. These studies generally examine the acute treatment period and at most 12 months beyond. Recently, a randomized study in patients with head and neck cancer showed that a radioprotector (amifostine) ameliorates some of the late toxicities (xerostomia) of chemo-radiotherapy [31] . Our study investigated late toxicities like nerve lesions, esophageal stenosis, and osteonecrosis. All patients had some degree of functional impairment. A surprisingly high number of patients (30-40%) had major late effects. The current aggressive approach has increased the cure rate in advanced head and neck cancer. With longer follow-up, more patients may develop late toxicities. A prospective comparison may determine to what extent late sequelae are due to chemotherapy and radiation. For the optimal quality of life, it is important to recognize, treat and, if possible, prevent these late toxicities. 
